A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.
The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.
advertisement
In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Gut bacteria may contribute to kidney autoimmunity, study finds
Next article： In Memoriam: Notable people who died in 2023
Next article： In Memoriam: Notable people who died in 2023
